CVRxCVRX
Recorded

CVRx 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration35 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this conference is being recorded. I will now turn the conference over to Mark Klausner from ICR Healthcare. Thank you, Mark. You may begin.

Mark KlausnerManaging Partner

Good afternoon. Thank you for joining us today for CVRx's third quarter 2026 earnings conference call. Joining me on today's call are the company's President and Chief Executive Officer, Kevin Hykes, and Jared Oasheim, our Chief Financial Officer, who will review our financial results. We are also pleased to have with us John Landry, the company's Incoming Chief Financial Officer, who joined in October and will assume the CFO role following the filing of our Form 10-Q. The remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings.

Mark KlausnerManaging Partner

I would now like to turn the call over to CVRx's President and Chief Executive Officer, Kevin Hykes.

Kevin HykesPresident and CEO

Thanks, Mark. Good afternoon, and thank you for joining our third quarter 2026 earnings call. We delivered total revenue of $13.8 million in the third quarter, within our guidance range, with a steady gross margin of 87%. Revenue declined 6.1% from the same quarter last year, with U.S. revenue down 4% and Europe down 27%. We continued to stabilize our U.S. sales organization, and a second major payer added a Barostim coverage policy for its Medicare Advantage enrollees. However, the headwinds we've been working through are more impactful and more persistent than we have anticipated, and while tenure is improving, the impact on performance is taking longer to materialize than we had expected, in part due to these headwinds. I want to give you a fuller picture of what is shaping our business.

Kevin HykesPresident and CEO

I'll cover three areas: the three headwinds we're facing, which are reimbursement, physician champion turnover, and field execution, and what we're doing about each, what is working in our most stable regions and how we're extending it, and the clinical evidence that's building behind Barostim. I will then introduce our incoming Chief Financial Officer, John Landry, before Jared reviews our financial results. The first headwind is reimbursement, specifically the change in behavior from our largest Medicare Advantage payer, which further degraded over the course of the third quarter. Our reimbursement visibility is limited to the prior authorizations that we are involved with, which likely represents less than half of all prior authorizations. For those that we handle directly, the approvals that previously occurred within days are now taking three months or longer.

Kevin HykesPresident and CEO

The 30-day approval rate with this particular payer has fallen to approximately 12% from a high of 83% in 2025, and the 90-day approval rate is still below 35%, suggesting that many prior authorizations are still in the appeals process, with our team pursuing all options, including ultimately an administrative law judge hearing, which can add 100 or more days to the approval process. For the prior authorizations associated with this payer that are handled directly by our customers, over 80% are likely abandoned upon the first denial. As a result of this dramatic change in payer behavior, we believe that some physicians are no longer recommending Barostim therapy for patients who have coverage with this payer, further weighing on our growth in the quarter.

Kevin HykesPresident and CEO

This decline was partially offset by an increase in approved prior authorizations for patients covered by Humana, but our overall Medicare Advantage approval rate declined to 51% at 30 days as of the end of Q3 from 60% in Q2. Longer term, we remain confident in our ability to overcome this transitory reimbursement challenge. Unfortunately, this effect goes beyond any single payer. Uncertainty around reimbursement for new therapies has caused some accounts to be more cautious about starting and scaling new programs. These accounts are implementing checkpoints to ensure consistent payment across their payer mix before committing to additional implants. This often means accounts will take time to assemble a group of patients with representative coverage policies, treat them, then pause to confirm or challenge payment with each payer.

Kevin HykesPresident and CEO

At one large health system, more than a dozen patients with approved prior authorizations have been on hold for multiple quarters while the hospital completes this payment confirmation process. We're responding to these reimbursement headwinds in multiple ways with the goal of accelerating Barostim adoption. First, we're continuing to appeal denials at every stage for prior authorizations that we manage on behalf of accounts, pursuing approvals all the way to an administrative law judge when necessary. Our success with Humana is proof that this process ultimately leads to a written coverage policy if we can prevail with the administrative law judges. Second, in recent months, we've hired field-based reimbursement managers to work directly with accounts to minimize billing and coding errors, ensure timely and accurate claims payments, and to troubleshoot with local teams when payment issues arise.

Kevin HykesPresident and CEO

Finally, we are using these same field-based resources to support and reduce the impact of increasingly lengthy payment trial periods that we are encountering in the market. At the same time, we continue to build a strong foundation of coverage for Barostim therapy. Since moving to a Category I code in January, we have secured our first two written Medicare Advantage coverage policies, one from Humana in the second quarter and from a second major payer in July. Together, these two policies represent 21% of Medicare Advantage covered lives. We are making progress on appeals and ALJ rulings with most payers, and each new written coverage policy strengthens our leverage with those payers that have not yet issued policies. Payment rates have also improved. Effective October 1, the national average inpatient payment rate increased from $43,000 to $45,000.

Kevin HykesPresident and CEO

On the outpatient front, the most recent traditional Medicare claims data shows 100% of submitted claims in Q1 of 2026 being paid, the first time we have achieved this consistency of payment. The second headwind is turnover among the heart failure specialists who are Barostim champions in our active accounts. Demand for heart failure specialists is outpacing supply as patient volumes continue to rise and fewer physicians are entering the specialty. This dynamic was a key point of discussion at the Heart Failure Society of America meeting last month. At HFSA, it was noted that more than 50% of advanced heart failure fellowship positions were unfilled in 2026. This imbalance is leading to a significant number of open roles and increasingly frequent career moves amongst practicing heart failure physicians.

Kevin HykesPresident and CEO

When a physician who is a Barostim champion in an active account leaves for a new employer, the Barostim program can slow or even stop altogether. Our field teams work to mitigate this disruption in two ways. The first is to build sustainable, resilient programs that integrate Barostim therapy into their heart failure treatment continuum. This reduces the likelihood that a single physician departure shuts a program down. The second is by supporting the physician as they move to their new practice, providing introductions, networking support, and resources to facilitate and accelerate the establishment of a new Barostim program in the new account. Unfortunately, we find that Barostim is not often an early priority for these physicians in their new roles, as they are often being recruited to help stabilize or accelerate highly profitable end-stage heart failure therapies such as left ventricular assist devices and heart transplantation.

Kevin HykesPresident and CEO

For this reason, it commonly takes three to four quarters to get a new Barostim program up and running. The third headwind is field execution, which is closely tied to the stability and tenure of our sales organization. Our sales transformation efforts have resulted in higher-than-normal levels of turnover, which has impacted our performance, and we are taking steps to address this. First, we have appointed Paul Verrastro to the role of interim head of sales. Paul is a proven commercial leader and is highly respected by the field team. The appointment of this trusted CVRx veteran to this role has had a significant stabilizing influence on our team.

Kevin HykesPresident and CEO

Second, we've created new roles in order to optimize the span of control and bandwidth of our frontline sales leaders and have prioritized filling these roles from within, promoting an experienced sales leader into our first area Vice President position and experienced territory managers into the area sales director roles. Third, we've strengthened onboarding and training for new hires and have implemented a more consistent sales coaching approach across our sales director team. These steps will take time to fully manifest in our results, but we are already seeing a positive impact on stability and engagement across the team. While it is still early, we're pleased to note that turnover in Q3 decreased to the lowest level in more than two years, and average territory manager tenure is at an all-time high. However, we remain cautious about the outlook for turnover.

Kevin HykesPresident and CEO

While these results represent meaningful progress, it is still early, and we expect continued turnover at normal market rates over the long term. That brings me to the most important point about execution. There are still significant disparities in performance across our nine U.S. regions. As noted in our second quarter call, five of our regions are growing procedures by more than 20% on average, even in the face of the reimbursement and physician champion headwinds described above. In the other four regions where we have the lowest tenure at both the territory manager and leadership levels, accelerating our growth has been challenging. These regions have been more affected by the headwinds discussed earlier, as their teams are less experienced at working through these challenges. Those four regions are our priority. We are stabilizing the teams, supporting our newer leaders, and equipping their organizations to consistently run our playbook.

Kevin HykesPresident and CEO

Our approach is the same in every region: execute our program selling strategy by building networks of aligned physicians who understand where Barostim fits in the heart failure continuum, who can identify patients who would benefit, and who make Barostim an integral part of their disease management approach. A recent comprehensive analysis of the program selling strategy after the first 18 months of implementation found that the key differentiator of our most productive programs is the depth and breadth of their referral network. Our analysis indicates that they have four to five times as many referring and prescribing cardiologists as less productive non-program accounts, and as a result, generate referrals and implants at a significantly higher rate. Our program development work at the account level is supported through our local, regional, and national medical education and awareness efforts.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day